Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.
Navratnas of the market: 9 investing mantras from Devina Mehra’s new book
Investment mantras aren’t morning chants you recite with closed eyes and crossed legs. “They are what you believe are at the foundation of your whole
April 14, 2025